WAVE LIFE SCIENCES LTD. Operating Lease Cost
WAVE LIFE SCIENCES LTD. (WVE) reported Operating Lease Cost of $7.37 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-26
- WAVE LIFE SCIENCES LTD. operating lease, cost for the quarter ending 2019-12-31 was $1.12M.
- WAVE LIFE SCIENCES LTD. operating lease, cost for the quarter ending 2019-09-30 was $1.12M.
- WAVE LIFE SCIENCES LTD. operating lease, cost for the quarter ending 2019-06-30 was $1.12M.
- WAVE LIFE SCIENCES LTD. operating lease, cost for the quarter ending 2019-03-31 was $1.12M.
- WAVE LIFE SCIENCES LTD. operating lease, cost for fiscal 2025 was $7.37M, a 0.00% change from fiscal 2024.
- WAVE LIFE SCIENCES LTD. operating lease, cost for fiscal 2024 was $7.37M, a 0.00% change from fiscal 2023.
- WAVE LIFE SCIENCES LTD. operating lease, cost for fiscal 2023 was $7.37M, a 14.04% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. operating lease, cost for fiscal 2022 was $6.46M, a 36.19% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $7.37M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $7.37M 10-K · filed 2026-02-26 | |||
| 2023-12-31 | $7.37M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | $6.46M 10-K · filed 2025-03-04 | |||
| 2021-12-31 | $4.74M 10-K · filed 2023-03-23 | |||
| 2020-12-31 | $4.47M 10-K · filed 2022-03-03 | |||
| 2019-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $2.24M derived: sum of 2 quarters · filed 2021-03-04 | $3.35M derived: sum of 3 quarters · filed 2021-03-04 | $4.47M 10-K · filed 2021-03-04 |
| 2019-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $2.24M derived: sum of 2 quarters · filed 2019-11-05 | $3.35M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $2.24M 10-Q · filed 2019-08-06 | ||
| 2019-03-31 | $1.12M 10-Q · filed 2019-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |